// App-Quantinova.ai

2276 : Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Researchers

Presenter

  • Shaji K. Kumar

Principal Investigators

  • Saad Z. Usmani

  • Torben Plesner

  • Robert Z. Orlowski

  • Cyrille Touzeau

  • Supratik Basu

  • Nizar Bahlis

  • Hartmut Goldschmidt

  • Michael O'Dwyer

  • Christopher P. Venner

  • Katja Weisel

  • Cyrille Hulin

  • Lionel Karlin

  • Meir Preis

  • Annemiek Broyl

  • William Renwick

  • Markus Hansson

  • Maria Krevvata

  • Jianping Wang

  • Rian Van Rampelbergh

  • Jon Ukropec

  • Clarissa M. Uhlar

  • Rachel Kobos

  • Aurore Perrot

Medical Centers

  • Department of Urology, Mayo Clinic, Rochester, MN, Rochester, MN

  • CHRU de Lille, Service des maladies du sang, Lille, France

  • Levine Cancer Institute, Charlotte, SC

  • Vejle Hospital and University of Southern Denmark, Vejle, Denmark

  • Dept of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

  • Hematology Biology, University Hospital Hotel Dieu, Nantes, France

  • Royal Wolverhampton Hospitals NHS Trust New Cross Hospital, Wolverhampton, United Kingdom

  • Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada

  • Department of Internal Medicine V and National Centre for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • ICORG and University College Hospital Galway, Galway, Ireland

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Department of Oncology, Haematology and Bone Marrow Transplantation with section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Hematology, Hospital Haut Leveque, University Hospital Bordeaux, Pessac, France

  • Department of Pathology, Lyon-Sud Hospital, Pierre-Benite, France

  • Carmel MC, Haifa, Israel

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Western Health, Sunshine Hospital, Cancer Services, St Albans, Victoria, Australia

  • Department of Oncology, Lund University Hospital, Lund, Sweden

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Global Medical Affairs, Horsham, PA

  • CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie,Toulouse,Frankreich

Locations

  • United States

  • France

  • Denmark

  • United Kingdom

  • Canada

  • Germany

  • Ireland

  • Israel

  • Netherlands

  • Australia

  • Sweden

  • Belgium

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Sparsentan

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved